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Objective: Facioscapulohumeral dystrophy (FSHD) is one of the most frequent heritable muscular dystrophies, with a
large variety in age at onset and disease severity. The natural history and molecular characteristics of FSHD in child-
hood are incompletely understood. Our objective is to clinically and genetically characterize FSHD in childhood.
Methods: We performed a nationwide, single-investigator, natural history study on FSHD in childhood.
Results: Multiple-source recruitment resulted in 32 patients with FSHD (0–17 years), leading to an estimated preva-
lence of 1 in 100,000 children in The Netherlands. This series of 32 children with FSHD revealed a heterogeneous phe-
notype and genotype in childhood. The phenotypic hallmarks of FSHD in childhood are: facial weakness with normal
or only mildly affected motor performance, decreased functional exercise capacity (6-minute walk test), lumbar hyper-
lordosis, and increased echo intensity on muscle ultrasonography. In addition, pain and fatigue were frequent and
patients experienced a lower quality of life compared to healthy peers. In contrast to the literature on early-onset
FSHD, systemic features such as hearing loss and retinal and cardiac abnormalities were infrequent and subclinical, and
epilepsy and intellectual disability were absent. Genotypically, patients had a mean D4Z4 repeat array of 5 units (range,
2–9), and 14% of the mutations were de novo.
Interpretation: FSHD in childhood is more prevalent than previously known and the genotype resembles classic FSHD.
Importantly, FSHD mainly affects functional exercise capacity and quality of life in children. As such, these results are
paramount for counseling, clinical management, and stratification in clinical research.
ANN NEUROL 2018;84:635–645
Facioscapulohumeral dystrophy (FSHD) is one of themost frequent heritable muscular dystrophies and typ-
ically affects the facial, scapulohumeral, tibial, and axial
muscles.1,2 The most frequent cause of FSHD, which is
currently the only reported cause of FSHD in childhood,
is partial loss of D4Z4 macrosatellite repeats in the subte-
lomere of chromosome 4q (FSHD type 1 [FSHD1];
OMIM 158900). FSHD1 patients have only 1 to 10 of
these D4Z4 repeats, whereas healthy individuals have 8 to
100 repeats.3 Loss of D4Z4 repeats results in partial
D4Z4 chromatin relaxation and derepression of the
DUX4 in skeletal muscles,4 a germ-line and cleavage stage
transcription factor encoded by a conserved open reading
frame within the D4Z4 repeat. Presence of DUX4 in skel-
etal muscle activates a series of transcriptional programs,
eventually leading to muscle cell death.4 In the rare form,
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FSHD2, D4Z4 chromatin relaxation and DUX4 derepres-
sion in skeletal muscle are caused by mutations in the
chromatin regulator, SMCHD1, or rarely DNMT3B.5,6
The FSHD phenotype encompasses a broad spectrum of
severity ranging from nonpenetrant mutation carriers to
severely affected patients.
Age at onset of FSHD varies from infancy to late
adulthood. Whereas most patients present in the second
or third decade of life, up to 21% of patients are estimated
to present in childhood.7 Initially, early-onset FSHD was
defined by (1) facial weakness before the age of 5 years
and (2) scapulohumeral weakness before the age of
10 years.8 In literature, early-onset FSHD is often
described as a severe subtype associated with one to three
D4Z4 repeats, severe muscle weakness, and frequent sys-
temic complications, including epilepsy, hearing difficul-
ties, retinal abnormalities (Coats’ syndrome), intellectual
disability, and cardiac arrhythmias.8–14
Currently, FSHD in childhood is often perceived as
synonymous to early-onset FSHD. Therefore, FSHD in
childhood is frequently described as being a severely affected
subgroup. However, this is solely based on case reports and
case series, and, in practice, we also encounter children with
milder phenotypes in our tertiary referral center. The full
spectrum of FSHD in childhood is therefore probably not
known. Furthermore, data on the prevalence, natural his-
tory, prognostic markers, and clinical management of
FSHD in childhood are limited. These data are critical for a
better and focused understanding of childhood FSHD, opti-
mal patient care, and improved clinical trial readiness.15 We
therefore instigated the first population-based, nationwide,
single-center study on childhood FSHD.
The objectives of this study are to (1) clinically and
genetically characterize FSHD in childhood and (2) esti-
mate the prevalence of FSHD in childhood in The
Netherlands.
Patients and Methods
Patients and Design
A nationwide, prospective, cross-sectional study was per-
formed. Eligible patients had clinically suspected FSHD,
defined as clinical weakness of the facial and/or upper arm
muscles for which the patient had sought medical atten-
tion with exclusion of other diagnoses. Patients were
17 years or younger and resided in The Netherlands.
Patients were recruited by (1) the database of our tertiary
referral center, which was established in 1986; (2) neurolo-
gists/pediatricians from all neuropediatric clinics in The
Netherlands; (3) the Department of Clinical Genetics of
the Leiden University Medical Centre, the single reference
center for genetic testing of FSHD in The Netherlands;
and (4) by social media groups focusing on FSHD. This
extensive recruitment ensured a high degree of inclusion
(protocol published previously16). Patients were recruited
from December 2015 until August 2017. Clinical and
molecular data were collected prospectively. This study
protocol has been approved by the Medical Review Ethics
Committee region Arnhem-Nijmegen (NL53213.091.15)
and is in accord with the ethical standards laid down in
the 1964 Declaration of Helsinki and its later amend-
ments. Written informed consent from participants aged
12 to 18 years and from parents/legal guardians of all par-
ticipants was obtained.
Mutation Analysis
Peripheral blood mononuclear cells were collected from
patients and their biological parents, if available, and high-
molecular-weight DNA and RNA was isolated. Sizing of
the D4Z4 repeats on chromosomes 4 and 10 was per-
formed by pulsed field gel electrophoresis (PFGE), fol-
lowed by Southern blotting using probe p13E-11.
Haplotype analysis was done by sequential hybridization
of PFGE Southern blots with probes A and B in combina-
tion with PCR-based simple-sequence length polymor-
phism analysis.3,17 We also established the methylation of
the D4Z4 repeat at the FseI restriction site in the proxi-
mal unit of the D4Z4 array.6,18 If appropriate, we tested
for mutations in SMCHD1 or DNMT3B by PCR amplifi-
cation of all coding exons followed by Sanger sequencing.6
Methylation values are expressed as the Delta1 score, that
is, the observed methylation minus the predicted methyla-
tion based on the D4Z4 repeat size.19 Delay in diagnosing
FSHD was defined as the time course between first symp-
toms/first medical assessment and the genetically con-
firmed diagnosis of FSHD.
Clinical Assessments
Clinical outcome measures were structured according to
the format of the International Classification of Function-
ing, Disability and Health for children and youth
(ICF-CY20; Supporting Information Appendix I) and all
measures were performed by one team (R.J.M.G., neurol-
ogist in training and M.J., pediatric physiotherapist).
The clinical phenotype was assessed by manual mus-
cle force testing (trapezius, deltoid, biceps, finger flexors,
quadriceps femoris, tibialis anterior, and gastrocnemicus
muscle)21 endurance by means of the 6-minute walk
test22–24 with calculation of the percent change in velocity
of the first- and last-minute distance.25 Patients were
graded by the FSHD clinical score26 and the age-adjusted
clinical severity scale.27,28 Both parents were assessed clini-
cally, and the clinical severity scale27 was determined. We
defined parents with a molecular diagnosis of FSHD as
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affected, asymptomatic (no reported symptoms and only
mild signs on clinical examination), or as nonpenetrant
(no reported symptoms and no signs on clinical examina-
tion). Muscle functions were tested by means of the
Motor Function Measure29,30 and the shoulder dimension
of the Performance of the Upper Limb (PUL) module.31
Quality of life and daily functioning were assessed
using educational level, pain score, the Kidscreen
questionnaire,32 and the NeuroQol fatigue domain.33
Normal values of the Kidscreen and the NeuroQoL were
provided by the investigators,32,33 and results are expressed
as standard deviations (SDs) from the mean.
Ophthalmologic examinations included visual acuity
using a Snellen chart, clinical examination by an ophthal-
mologist, fundusphotography, and optical coherence
tomography (OCT), as well as OCT angiography for spe-
cific examination of the fovea.34 A tone and speech audi-
ometry was performed to detect (sub)clinical hearing loss
and an electrocardiogram (ECG) to detect cardiac
abnormalities.
Muscle Ultrasound Analysis
All ultrasound examinations were performed on a MyLab
Twice muscle ultrasound (MUS) system (Esaote, Genoa,
Italy), using a 3- to 13-MHz broadband linear transducer
(LA533). Quantative muscle ultrasound (QMUS) measure-
ments etc. were performed to determine echo intensity of
the masseter, trapezius, biceps brachii, rectus abdominis,
rectus femoris, gastrocnemius, and tibialis anterior muscles,
bilaterally. Choice of muscles was based on the frequency
of involvement described in FSHD35 and the availability of
US normal values (therefore no facial muscles typically
affected in FSHD were imaged). A fixed scanning proto-
col36 was used and the captured images were analyzed for
echo intensity by means of computer-assisted grayscale his-
togram analysis, using custom software (QUMIA). Echo
intensity was compared to muscle specific reference values
and expressed as z-score, a robust measure for qMUS analy-
sis analysis.37
Statistical Analysis
Statistical analysis was performed using SPSS (version
22.0; SPSS, Inc., Chicago, IL)38 and Prism software (ver-
sion 5; GraphPad Software Inc., San Diego, CA). Para-
metric variables are expressed as mean ± SD.
Nonparametric data are expressed as median [interquartile
range]. Student t and Mann-Whitney U tests were used
for comparing the numerical data. Results of the Neuro-
Qol fatigue scale, 6-minute walk test, and Kidscreen were
expressed as the number of SDs from the mean (z-score).
A p value < 0.05 was considered statistically significant.
To investigate possible differences between early-onset
FSHD and classic FSHD, subgroup analysis were done on
three subgroups: (1) patients with “early-onset FSHD”
based on the following criteria: (i) signs or symptoms of
facial weakness before the age of 5 years and (ii) signs or
symptoms of scapular weakness before the age of 10 years8;
(2) patients with “classic FSHD” (eg, those with onset after
the age of 10 years); and (3) patients who were too young
to be classified in one of the above categories.
Results
Demographics
A total of 38 children were identified as possible partici-
pants: 28 by the national genetic reference center database
and 10 children with clinically suspected FSHD by other
recruitment sources. Of these 10 children with clinically
suspected FSHD, FSHD was molecularly confirmed in
4 children. In 3 children, a different diagnosis was found
(mitochondrial myopathy, celiac disease, and chronic
fatigue syndrome), and the other 3 had a physiological
asymmetry in facial and/or scapular muscles without the
underlying genetic defect known in their families. A total of
32 children with genetically confirmed FSHD were identi-
fied (Fig 1). The total number of children aged 0 to
18 years in The Netherlands is 3.416.581 (Statistics Neth-
erlands39), leading to a lower-bound prevalence estimate of
1 in 100,000. Of the 32 children, 28 participated in the
study (19 at the study location, 3 at home, and 6 with
medical file review). Four patients did not participate, but
their age at onset and genetic characteristics were known:
1 patient refused participation because of the parents’ fear
for the emotional burden of the genetic results; the other
3 could not be identified or traced (Fig 1). Participants
were aged 2 to 17 years with a mean age at examination of
11.5 years and a mean age at onset of 6.7 years. Clinical
and genetic characteristics can be found in Table 1. Crea-
tine kinase was moderately increased with a mean of 180U/
l; levels ranged from 37 to 500U/l (normal-to-moderate
increase).
FIGURE 1: Flow diagram of patient recruitment and
inclusion. FSHD = facioscapulohumeral dystrophy.
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Genetic Characteristics
Average diagnostic delay of FSHD in childhood was
3.1 years (range, 0–9). Six patients did not have a genetic
diagnosis before enrollment in the study. The reason for
abstaining from earlier genetic testing was the possible
emotional burden for the child combined with the lack of
TABLE 1. Clinical and Genetic Characteristics
Demographics N Mean Range SD
Age at examination (y) 32 12 4 to 17 5
Male sex, no. (%) 14 (44)
D4Z4 repeat arrays, mean (range, SD) 32 5.2 2 to 10 2.0
Methylation score, mean (range, SD) 12 –6.18 –13 to 5 5.2
De novo mutations, no./total no. (%) 3/22 (14)
Mosaic inheritance, no./total no. (%) 0/22 (0)
SMCHD1 mutation 1/22
Motor Functioning
Facial weaknessa 21/25
Scapular weakness (PUL)b 4/12
Motor function measure 18 99.4% 96% to 100% 1.1
MRC sum score (0–70) 12 68.1 54 to 70
Six-minute walk test (number of SDs) 12 –2.2 –5.24 to –0.9
Clinical severity scale (CSS, 0–10) 20 2.5 0 to 6 1.5
Age-corrected CSS (0–2,000) 20 448 0 to 1,200 306
FSHD evaluation score (0–15) 20 2.3 0 to 6 1.5
Systemic Features Measured Complaints Investigational Findings
Hearing loss 29 0 3/19 high-frequency loss on audiometry (16%)
Vision loss 22 0 5/9 retinopathy on fundoscopy (56%)
Epilepsy, no./total no. 27 0 0/2 abnormalities on EEG
Intellectual disability 27 0c
Cardiac abnormalities 22 1 4/22 abnormalities on ECG
Lumbar hyperlordosis 24 3dd 9/24e
Assisted ventilation 32 0 1/9 decreased spirometry
Swallowing difficulties 22 1 0/12 swallowing abnormalities
Dysarthria 22 5 3/22 mild dysarthria on speech language examination
aBased on one or more points on the facial weakness domain of the FSHD clinical score.
bPerformance of the upper limb shoulder module.31
cDefined by school level; none of the patients attended specialized education.
dBased on complaints of upper or lower back pain.
eBased on clinical examination of the spine.
CSS = Clinical Severity Score; ECG = electrocardiogram; EEG = electroencephalogram; FSHD = facioscapulohumeral dystrophy; MRC = Medical
Research Council; PUL = Performance of Upper Limb; SD = standard deviation.
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curative treatment. In contrast, 5 patients from three fami-
lies had elected presymptomatic testing after genetic
counseling.
Of the 28 patients, 6 declined venipuncture and in
the other 22 patients both the child and parents were
genetically tested. In 19 cases (86%), an autosomal-
dominant transmission was found, eight paternal and
11 maternal transmissions. In the other 3 cases (14%), the
mutation had occurred de novo as a germinal mutation.
Somatic mosaicism was not observed. The parents of
3 patients had been diagnosed after their children were
diagnosed: 1 was nonpenetrant, and the other 2 were
asymptomatic with mild facial and scapular weakness.
Mean number of units within the pathogenic D4Z4
repeat was 5.2 (SD, 2; range, 2–10). In 12 children, com-
prehensive genetic characterization was performed, show-
ing delta1 scores below –10% in 5, but not below the
threshold for FSHD2 (–21%). Another patient was diag-
nosed with FSHD2 and carried a pathogenic SMCHD1
variant. No significant correlation between mean number
of units within the pathogenic D4Z4 repeat and disease
severity (as measured by the FSHD clinical score, the age-
adjusted clinical severity scale, and the motor function
measure) or age at onset was observed (Spearman r,
all p > 0.05).
Clinical Characteristics
Muscle Functioning. Muscle strength and muscle perfor-
mance ranged from normal to mildly reduced with a mean
MRC sum score of 68 of 70 points (range, 54–70; SD,
2.26), and a Motor Function Measure (MFM) of 99% of
100% (range, 96–100; SD, 1.1). Asymmetry of the Medi-
cal Research Council (MRC) score was noted in 4 of
8 patients with a decreased MRC sum score. Lower scores
on the MFM were almost exclusively found in the axial
and proximal functioning dimension. Four of 12 tested
patients had a decreased shoulder-arm function as assessed
by the PUL test. These 4 patients were not able to stack
or raise cans on different axes, and all showed compensa-
tory strategies such as protraction or elevation of the
trunk. In 5 of 12 tested patients, a hamstring shortening
was noticed.
Functional exercise capacity, measured by the
6-minute walk test, was significantly below the mean for
sex and age (mean, –2.1 SDs; range, –5.2 to 0.9; SD, 1.5;
one-sample t test, t = 5.29; p < 0.0001). The patient with
the poorest performance on the 6-minute walk test
(z-score, –5.2) used a wheelchair for longer distances.
Average gait velocity decrease between the first and last
minute was 9.6% (82m in the first minute versus 73m in
the sixth minute; paired t test, p = 0.002). Mean (range,
SD) clinical severity scale was 2.5 of 10 points (0–6, 1.5
points), and mean (range, SD) FSHD evaluation score
was 2.3 of 15 points (0–6, 1.5 points).
Muscle US. Quantitative muscle US showed increased
echo intensity (ie, mean gray level of muscle images),
pointing to muscle fibrosis and/or fatty degeneration in
the trapezius, biceps brachii, rectus femoris, tibialis ante-
rior, rectus abdominis, and gastrocnemius on both sides.
Echo intensity asymmetries between left and right side
were observed in all muscles. The masseter was the only
unaffected muscle in all patients. Severity of muscle US
abnormalities was heterogenic ranging from completely
normal (n = 6) to severely affected (mean MUS echo
intensity, 2.5 SDs above average; n = 4). The composite
sum score of all measurements combined showed a mean
of 1.4 SD above average (Fig 2). All clinically affected
muscles had an increased echo intensity, but not all the
muscles with increased echo intensity were clinically
affected.
Systemic Features. Mild spinal posture abnormalities
were frequent; 5 of 18 patients had an increased lumbar
hyperlordosis, and 2 of 18 patients had a scoliotic posture.
In none of them was surgical correction required. Three
of these 5 patients with lumbar hyperlordosis showed
severe abdominal muscle involvement and 2 mild abdomi-
nal muscle involvement on muscle US.
Clinically relevant systemic features of FSHD were rare
in this cohort: none of the patients or parents reported
FIGURE 2: Combined ultrasound measurements of
14 participants showing the z-score of quantified echo
intensity. The z-score corresponds to the number of standard
deviations from the mean score for age and sex and weight
using established reference values. This shows that the
masseter is similar to reference values whereas all other
muscles (trapezius, biceps brachialis, rectus femoris, tibialis
anterior, rectus abdominis, and gastrocnemius) have
increased echo intensity.
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difficulties of hearing, vision, intellect or development, epi-
lepsy, and heart or pulmonary functioning. We only detected
subclinical findings with additional investigations. In 3 of
19 patients, subclinical hearing loss was detected with audi-
ometry; 2 patients had high-tone frequency loss (which is
associated with FSHD), and 1 patient had a conductive hear-
ing deficit (which is not associated with FSHD). All patients
had a normal visual acuity, and none had abnormalities dur-
ing ophthalmologic examination. On fundoscopy, retinal
abnormalities were frequently observed (6 of 10 patients)
consisting of tortuosity of arterial retinal vessels. Capillary
leakage or other progressive symptoms of retinal vasculopathy
were not found (Fig 3). One patient experienced fatigue and
dyspnea at the age of 8 years caused by a patent ductus arter-
iosus; no other cardiac symptoms were found. ECG revealed
minor cardiac abnormalities without clinical consequences:
1 patient with first-degree atrioventricular block; 1 with pre-
mature ventricular contractions; and 1 with right-axis devia-
tion. Speech language exam revealed mild dysarthria in
3 patients attributed to decreased lip and facial muscle func-
tion and 1 patient with swallowing difficulties. No other gas-
trointestinal or feeding difficulties were reported. None of the
patients had symptoms of decreased respiratory function or
needed assisted ventilation.
Pain and Daily Life Activities
Pain was a frequent complaint (63%; 15 of 24). Pain dur-
ing or after prolonged exertion was frequent and located
in the lower back, shoulder region, and/or legs. Fatigue
was reported in 83% (20 of 24), and the NeuroQol
fatigue questionnaire showed that all participants experi-
enced more fatigue than in the general pediatric popula-
tion (mean, 1.1 SD above average). Quality of life was
lower on all domains with a mean SD of 0.9 below aver-
age. Specifically, the physical domain was below average
(1.5 SD), which corresponds to feelings of exhaustion,
feeling unwell, and low energy levels Table 2. All patients
attended regular education and participated in after school
activities such as sports or music. Parent questionnaires
were comparable to the scores of their children.
Early-Onset FSHD Classification
Nine patients fulfilled the criteria for early-onset FSHD,8
17 patients had a classic onset, and 6 patients were too
young for classification. Mean (range, SD) current age was
10 years (4–17, 3.5) in the early-onset group and 15 years
(9–17, 2.6) in the classic onset group. Early-onset FSHD
patients had a shorter repeat length (3.9 versus 5.8 number
of units within the pathogenic D4Z4 repeat; Mann-Whitney
U, 29.50; p = 0.03), a higher FSHD evaluation score
(3.7 versus 1.8; Mann-Whitney U, p = 0.03), and a higher
quantitative MUS score (3.2 versus 0.8 mean SDs above
average; nonpaired t test, p < 0.005) compared to the classic-
onset group. The 6-minute walk test, MFM, and MRC sum
score did not differ significantly between the two groups.
Individual patient characteristics can be found in Table 3.
Discussion
This study shows that the clinical spectrum of FSHD in
childhood is more heterogeneous than previously reported.
In this nationwide study with the largest cohort to date,
FSHD in childhood is characterized by facial weakness with
otherwise normal muscle strength and performance, limited
functional exercise capacity, lumbar hyperlordosis, a
decreased quality of physical well-being, and the presence of
fatigue and pain. Systemic features are rarely reported. Chil-
dren with FSHD attend regular schools and extracurricular
activities. In general, these findings show that in children, the
complete spectrum of classic FSHD is observed instead of the
very severe phenotype of early-onset FSHD.
We found a lower-bound estimated prevalence of
FSHD in childhood of 1 per 100,000. This is markedly
FIGURE 3: Fundusphotography of 2 independent FSHD patients showing veins (darker and larger in diameter) and arteries
(brighter with a central luminance and thinner diameter). (A) Patient 7 with normal appearance of retinal arteries. (B) Patient
9 with severe tortuosity and broader reflex of the retinal arteries (white arrows), but normal appearance of the retinal veins.
FSHD = facioscapulohumeral dystrophy. [Color figure can be viewed at www.annalsofneurology.org]
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higher than the previously reported 0.29 per 100,000.40
The higher prevalence is likely to be caused by active
recruitment resulting in inclusion of the mildly affected
children who were not included in earlier prevalence stud-
ies. Hence, FSHD is a relatively frequent muscular dystro-
phy in childhood, approaching the prevalence of myotonic
dystrophy in children (1.41 per 100,000). Consequently,
it should be considered in children with facial weakness,
axial weakness with spinal deformities, and/or scapulo-
humeral dysfunction. As such, it is an important differen-
tial diagnosis of congenital myopathies and congenital
myasthenic syndromes. Total FSHD prevalence estimates
in literature are, on average, 5 per 100,000,2 leading to an
estimated 20% who have a childhood onset.
Genetic characteristics in our cohort were similar to
genetic characteristics reported in the adult population:
both regarding the repeat size (mean 5.3 units in our
cohort versus 5.8 units in an adult white FSHD popula-
tion41) and frequency of FSHD2 (3.7% versus 5%6).
Additionally, whereas the frequency of de novo mutations
tends to be higher in early-onset FSHD (73%42), our
cohort showed a lower frequency (14% in the whole
group, 22% in the early-onset subgroup), which is more
in line with classic onset FSHD with de novo mutations
in up to 30%43). A correlation between disease severity
and the repeat size, as found in earlier research,44 was not
demonstrated in this cohort. This could be attributed to
the difficulty defining disease severity at a very young age
and the cohort size. We did find a shorter repeat length in
the early-onset group compared to the classic onset group.
In conclusion, the genotype of FSHD in childhood resem-
bles the genotype of FSHD in adults.
This study has identified two important motor fea-
tures in childhood FSHD. First, we observed a limited
functional exercise capacity and structural muscle abnormal-
ities on muscle ultrasonography in patients with normal to
mildly reduced muscle strength as measured with manual
muscle testing and normal muscle performance on the
MFM. This is in line with observations in Duchenne mus-
cular dystrophy showing widespread muscle fibrosis early in
the disease course, first resulting in decreased functional
exercise capacity followed by muscle weakness45; our data
could suggest a similar sequence in FSHD. Another expla-
nation could be the insensitivity of the MFM on muscle
performance. Second, we frequently observed postural
abnormalities and abdominal muscle involvement on mus-
cle ultrasonography, thereby pointing to early axial muscle
involvement in FSHD, as described in adults by others46
and our group.47 In addition, hamstring shortening was fre-
quently observed, which can be caused by increased tho-
racic kyphosis and which was noted in the sitting position.
Early recognition of spinal deformities is important for ade-
quate management of pain and respiratory function.48
The relative low prevalence of central nervous sys-
tem features in our cohort also supports the heterogeneous
clinical spectrum of FSHD in childhood: The frequency
of hearing loss, vision loss, epilepsy, and intellectual dis-
ability was low and similar to those in adults with classic
FSHD.12,49 The hypothesis that central nervous system
signs present later in life is unlikely attributed to the
TABLE 2. Quality of Life in Children With FSHD as Measured by the Kidscreen and the NeuroQol Fatigue Scale
N Mean SD Childa Mean SD Parenta Meaning
NeuroQoL 8-item fatigue bank 10 1.1 1.2 Experiencing more fatigue
Kidscreen total 9 −0.9 −0.7
Kidscreen subdomains:
Physical well-being −1.5 Feeling exhausted, unfit
Psychological well-being −1.0 Dissatisfaction with life
Autonomy −0.7 Feeling restricted
Parent relation and home life −0.8 Feeling alone, overlooked
Financial resources −0.7 Feeling financially disadvantaged
Social support and peers −0.8 Feeling excluded, not accepted
School environment −0.7 Disliking school, not doing well
Social acceptance Insufficient number of replies
aCompared to healthy subjects.
FSHD = facioscapulohumeral dystrophy; SD = standard deviation.
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TABLE 3. Individual Clinical and Genetic Features of Patients Aged 0 to 18 Years With FSHD
#
Age,
Sex
Onset
Agea
Onset
Type D4Z4b
Delta
Scorec
Hereditary
Pattern
MFM
(%)
FSHD
Score
Ac
Scored SMWT
Systemic
Features MUSe
1 0, M pre na 4 Maternal na 0 0 na n −0.58
2 2, F pre na 4 Maternal na 0 0 na n –0.33
3 4, M pre na 5 Paternal na 0 0 na n
4 4, M 1 e 2 −3 Paternal 100 2 1,000 −1.65 Mild RT
hearing loss
5 6, F 1 na 2 −7 Paternal 100 2 667 −2.08 Severe RT 1.59
6 6, M 3 na 5 Maternal 100 2 667 n
7 6, M pre na 7 Familial 0 0 u
8 8, M 4 e 4 Maternal 100 3 250 −3.00 n
9 8, F 3 e 5 Maternal 0 0 ECG1
10 9, F 1 e 8 Maternal 96 2 222 −3.20 Mild RT 2.85
11 9, F 8 c 4 −12 Paternal 99 3 667 n 0.21
12 10, M 7 e 2 −11 Sporadic 96 6 1,200 −2.71 LH, severe RT
hearing loss
3.55
13 10, M 5 e 5 Maternal 2 400 u
14 11, F 6 c 7 −8 Maternal 99 3 182 −5.24 LH, mild RT 1.42
15 11, M 1 e 5 −10 Maternal 99 6 364 −2.50 LH, S 2.86
16 11, F 4 c 4 −2 Paternal 100 3 182 −1.44 LH, mild RT 0.44
17 11, F 1 e 2 −11 Sporadic 99 6 182 −0.95 LH, severe RT 3.53
18 14, F 11 c 7 −4 Maternal 98 2 143 −2.14 n –0.29
19 14, M 12 c 6 Paternal 100 0 0 n
20 14, F u c 8 Familial u
21 15, M 2 c 3 Maternal 100 3 333 LH
22 15, F 8 c 5 Maternal 100 1 67 u
23 16, F 15 c 6 −4 Paternal 99 2 313 −3.17 S, ECG2 0.79
24 16, M 12 c 6 −14 Maternal 100 2 125 ECG3
25 17, F 10 c 7 5 u 99 1 59 0.90 n 1.05
26 17, M 13 c 5 u 100 2 176 n
27 17, F 16 c 7 −13 Maternal 100 1 118 −1.60 Mild RT
hearing loss
1.78
28 17, F u c 10 Paternal 100 2 118 n
29 17, M 3 e 5 Paternal u
30 17, F 9 c 5 u 100 3 n
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suspected underlying genetic mechanisms.11,50 The most
likely explanation for the discrepancy with previous stud-
ies on early-onset FSHD8,11,13 is selection and publication
bias of the published cases.
Many patients reported fatigue (83%), pain (63%),
and a decreased quality of life (70%). This is in accord
with a previous study in adults showing high disease bur-
den, with 61% having severe fatigue,51 56% reporting at
least mild/moderate pain, and all quality-of-life domains
being impaired.52 This decreased quality of life is in con-
trast to reports on Duchenne muscular dystrophy, where a
quality of life similar to healthy peers was found.53 Expla-
nations could be the sampling method of the question-
naires, the burden of facial weakness resulting in impaired
social contact, the high frequency of pain,54 and/or a lim-
ited functional exercise capacity, which could be amplified
by the absence of visible signs of a myopathy.
Based on our results, the management of FSHD in
childhood should focus on facial weakness, pain, fatigue,
functional exercise capacity, and quality of life. Recom-
mended sensitive outcome measures for clinical trials are the
6-minute walk test, which has been validated and frequently
used in other pediatric neuromuscular diseases55,56 and mus-
cle ultrasonography, which even showed abnormalities in
patients with otherwise completely normal neurological
examination in our cohort similar to infants with Duch-
enne.57 In future studies, it would be interesting to look at
additional functional exercise capacity tests targeting the
upper extremities as well. Currently, there are no evidence-
based therapies for FSHD in childhood. It could therefore
be useful to test the effect of symptomatic interventions, such
as aerobic exercise training58 or cognitive behavioral
therapy,59 on fatigue and quality of life in children.
This study has a number of limitations. Most impor-
tant, missing data were frequent because of the specific
patient population. Some patients and parents wished to
participate only by home visits or medical file investiga-
tions; some patients were too young for testing (minimal
ages can be found in Supporting Information Appendix
A), or had difficulty with understanding the instruction,
or had unsatisfactory motivation (specifically in quality-of-
life questionnaires and blood withdrawal; spirometry fre-
quently failed because of inadequate mouth closure).
Another limitation is the incomplete inclusion. Four of
the 32 patients were not included in the study. However,
clinical follow-up showed that 3 were asymptomatic or
only mildly affected, and the fourth was lost to follow-up.
Therefore, our disease severity may rather be an overesti-
mation than an underestimation. Last, the tests for motor
functioning were possibly not sensitive enough; for future
testing, we would recommend hand-held dynamometry or
quantified muscle testing methods and more exercise
capacity measurements.
In this nationwide study, FSHD in childhood is
characterized by facial weakness without impaired muscle
strength and performance, decreased functional exercise
capacity, decreased quality of life, and a broader clinical
phenotype and genotype than previously expected. This
research will serve as a basis for future natural history
studies. Additionally, muscle ultrasonography and the
6-minute walk test are sensitive for disease pathology in
childhood FSHD, and therefore additional longitudinal
studies on these promising biomarkers are justified.
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TABLE 3. Continued
#
Age,
Sex
Onset
Agea
Onset
Type D4Z4b
Delta
Scorec
Hereditary
Pattern
MFM
(%)
FSHD
Score
Ac
Scored SMWT
Systemic
Features MUSe
31 17, F 13 c 5 u 100 1 118 ECG4
32 17, M 15 c FSHD2 Paternal 100 2 111 u
aAge at first symptom.
bMean number of units within the pathogenic D4Z4 repeat.
cThe observed methylation minus the predicted methylation based on the D4Z4 repeat size.
dThe age-adjusted clinical severity scale.
eMean z-score of the echo intensity per muscle.
# = case number.
Ac = age corrected; c = classic-onset FSHD; e = early-onset FSHD; ECG1 = patent ductus arteriosus; ECG2 = right-axis deviation; ECG3 = first
degree AV-block; ECG4 = sporadic premature ventricular contractions; F = female; FSHD = facioscapulohumeral dystrophy; LH = mild lumbar
hyperlordosis posture; M = male; MFM = Motor Function Measure; n = normal/no abnormalities; na = not applicable; pre = presymptomatic;
RT = retinal tortuosity; S = scoliotic posture; SMWT = six-minute walk test; u = unknown.
November 2018 635
Goselink et al: Facioscapulohumeral Dystrophy in Childhood
We thank all patients, parents, and sponsors for their
time and effort in this study. In addition, we would like to
acknowledge the following people who have contributed to
the study: Edith Cuppen, Yvonne Dominicus, Pauline
Gans, Bregje Jaeger, Henny Jansen, Nelly Lemmens, Erik
Niks, Sytske Nawijn, Joost Nicolai, Maaike Pelsma, Wilma
Raijmakers, Vivian Schreur, Bas Stunnenberg, Linda
Verhaegh, Astrid Verhoef, and Jack Weeda.
Author Contributions
Authors involved in the study concept and design were:
R.G., T.S., N.A., I.G., N.V., S.M., B.E., and
C.E. Authors involved in the data acquisition and analysis
were: R.G., M.J., T.T., P.V., R.L., S.M., B.E., and
C.E. Authors involved in drafting the text and figures
were: R.G., T.S., N.A., I.G., N.V., S.M., B.E., and C.E.
Potential Conflicts of Interest
Nothing to report.
References
1. Padberg GW. Facioscapulohumeral disease. Leiden, The
Netherlands: University of Leiden; 1982.
2. Deenen JC, Arnts H, van der Maarel SM, et al. Population-based
incidence and prevalence of facioscapulohumeral dystrophy. Neurol-
ogy 2014;83:1056–1059.
3. Lemmers RJ, de Kievit P, Sandkuijl L, et al. Facioscapulohumeral
muscular dystrophy is uniquely associated with one of the two vari-
ants of the 4q subtelomere. Nat Genet 2002;32:235–236.
4. Tawil R, van der Maarel SM, Tapscott SJ. Facioscapulohumeral dys-
trophy: the path to consensus on pathophysiology. Skelet Muscle
2014;4:12.
5. van den Boogaard ML, Lemmers RJ, Balog J, et al. Mutations in
DNMT3B modify epigenetic repression of the D4Z4 repeat and the
penetrance of facioscapulohumeral dystrophy. Am J Hum Genet
2016;98:1020–1029.
6. Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an
SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes
facioscapulohumeral muscular dystrophy type 2. Nat Genet 2012;44:
1370–1374.
7. Dorobek M, Van Der Maarel SM, Lemmers RJ, et al. Early-onset
facioscapulohumeral muscular dystrophy type 1 with some atypical
features. J Child Neurol 2014;30:580–587.
8. Brouwer OF, Padberg GW, Wijmenga C, Frants RR. Facioscapulo-
humeral muscular dystrophy in early childhood. Arch Neurol 1994;
51:387–394.
9. Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in
a subset of early onset 4q35-facioscapulohumeral muscular dystro-
phy. Neurology 1998;50:1791–1794.
10. Klinge L, Eagle M, Haggerty ID, et al. Severe phenotype in infantile
facioscapulohumeral muscular dystrophy. Neuromusc Disord 2006;
16:553–558.
11. Trevisan CP, Pastorello E, Tomelleri G, et al. Facioscapulohumeral
muscular dystrophy: hearing loss and other atypical features of
patients with large 4q35 deletions. Eur J Neurol 2008;15:1353–1358.
12. Lutz KL, Holte L, Kliethermes SA, Stephan C, Mathews KD. Clinical
and genetic features of hearing loss in facioscapulohumeral muscular
dystrophy. Neurology 2013;81:1374–1377.
13. Chen TH, Lai YH, Lee PL, et al. Infantile facioscapulohumeral muscu-
lar dystrophy revisited: Expansion of clinical phenotypes in patients
with a very short EcoRI fragment. Neuromusc Disord 2013;23:
298–305.
14. Nikolic A, Ricci G, Sera F, et al. Clinical expression of facioscapulo-
humeral muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles:
experience of the FSHD Italian National Registry. BMJ Open 2016;6:
e007798.
15. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management
of Duchenne muscular dystrophy, part 1: diagnosis, #and |neuromus-
cular, #rehabilitation, |endocrine, and gastrointestinal and nutritional
management. Lancet Neurol 2018;17:251–267.
16. Goselink RJ, Schreuder TH, Mul K, et al. Facioscapulohumeral dys-
trophy in children: design of a prospective, observational study on
natural history, predictors and clinical impact (iFocus FSHD). BMC
Neurol 2016;16:138.
17. Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic
model for facioscapulohumeral muscular dystrophy. Science 2010;
329:1650–1653.
18. van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. Hypomethylation
of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscu-
lar dystrophy. Nat Genet 2003;35:315–317.
19. Lemmers RJ, Goeman JJ, van der Vliet PJ, et al. Inter-individual dif-
ferences in CpG methylation at D4Z4 correlate with clinical variability
in FSHD1 and FSHD2. Hum Mol Genet 2015;24:659–669.
20. WHO. ICF-CY: International Classification of Functioning, Disability
and Health. Geneva, Switzerland: World Health Organization (WHO);
2015.
21. Vanhoutte EK, Faber CG, van Nes SI, et al. Modifying the Medical
Research Council grading system through Rasch analyses. Brain
2012;135:1639–1649.
22. ATS Committee on Proficiency Standards for Clinical Pulmonary
Function Laboratories. ATS statement: guidelines for the six-minute
walk test. Am J Respir Crit Care Med 2002;166:111–117.
23. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test
as a new outcome measure in Duchenne muscular dystrophy. Muscle
Nerve 2010;41:500–510.
24. Geiger R, Strasak A, Treml B, et al. Six-minute walk test in children
and adolescents. J Pediatr 2007;150:395–399, 399.e1–2.
25. Montes J, McDermott MP, Martens WB, et al. Six-Minute Walk Test
demonstrates motor fatigue in spinal muscular atrophy. Neurology
2010;74:833–838.
26. Lamperti C, Fabbri G, Vercelli L, et al. A standardized clinical evalua-
tion of patients affected by facioscapulohumeral muscular dystrophy:
the FSHD clinical score. Muscle Nerve 2010;42:213–217.
27. Ricci E, Galluzzi G, Deidda G, et al. Progress in the molecular diag-
nosis of facioscapulohumeral muscular dystrophy and correlation
between the number of KpnI repeats at the 4q35 locus and clinical
phenotype. Ann Neurol 1999;45:751–757.
28. van Overveld PG, Enthoven L, Ricci E, et al. Variable hypomethyla-
tion of D4Z4 in facioscapulohumeral muscular dystrophy. Ann Neurol
2005;58:569–576.
29. Bérard C, Payan C, Hodgkinson I, Fermanian J; MFM Collaborative
Study Group. A motor function measure for neuromuscular diseases.
Construction and validation study. Neuromusc Disord 2005;15:
463–470.
30. de Lattre C, Payan C, Vuillerot C, et al. Motor function measure: vali-
dation of a short form for young children with neuromuscular dis-
eases. Arch Phys Med Rehabil 2013;94:2218–2226.
636 Volume 84, No. 5
ANNALS of Neurology
31. Mayhew A, Mazzone ES, Eagle M, et al. Development of the Perfor-
mance of the Upper Limb module for Duchenne muscular dystrophy.
Dev Med Child Neurol 2013;55:1038–1045.
32. Ravens-Sieberer U, Gosch A, Rajmil L, et al; Kidscreen Group E.
KIDSCREEN-52 quality-of-life measure for children and adolescents.
Expert Rev Pharmacoecon Outcomes Res 2005;5:353–364.
33. Gordijn M, Cremers EM, Kaspers GJ, Gemke RJ. Fatigue in children:
reliability and validity of the Dutch PedsQL Multidimensional Fatigue
Scale. Qual Life Res 2011;20:1103–1108.
34. Statland JM, Sacconi S, Farmakidis C, et al. Coats syndrome in
facioscapulohumeral dystrophy type 1: frequency and D4Z4 contrac-
tion size. Neurology 2013;80:1247–1250.
35. Gerevini S, Scarlato M, Maggi L, et al. Muscle MRI findings in facios-
capulohumeral muscular dystrophy. Eur Radiol 2016;26:693–705.
36. Scholten RR, Pillen S, Verrips A, Zwarts MJ. Quantitative ultrasonog-
raphy of skeletal muscles in children: normal values. Muscle Nerve
2003;27:693–698.
37. Zaidman CM, van Alfen N. Ultrasound in the assessment of myo-
pathic disorders. J Clin Neurophysiol 2016;33:103–111.
38. IBM SPSS Statistics for Windows [computer program]. Version 22.0.
Armonk, NY: IBM Corp.; 2013.
39. Netherlands S. Statistics Netherlands [online]. Available at: https://
opendata.cbs.nl/statline/#/CBS/nl/dataset/37296ned/table?ts=15380
76312748 Accessed date: 4 May 2018. Publication date: 18 April
2018.
40. Mah JK, Korngut L, Fiest KM, et al. A systematic review and
meta-analysis on the epidemiology of the muscular dystrophies. Can
J Neurol Sci 2016;43:163–177.
41. Lemmers RJ, van der Wielen MJ, Bakker E, Frants RR, van der
Maarel SM. Rapid and accurate diagnosis of facioscapulohumeral
muscular dystrophy. Neuromuscul Disord 2006;16:615–617; author
reply, 617–618.
42. Goselink RJ, Voermans NC, Okkersen K, et al. Early onset faciosca-
pulohumeral dystrophy—a systematic review using individual patient
data. Neuromuscul Disord 2017;27:1077–1083.
43. Zatz M, Marie SK, Passos-Bueno MR, et al. High proportion of new
mutations and possible anticipation in Brazilian facioscapulohumeral
muscular dystrophy families. Am J Hum Genet 1995;56:99–105.
44. Tawil R, Kissel JT, Heatwole C, et al. Evidence-based guideline sum-
mary: evaluation, diagnosis, and management of facioscapulohum-
eral muscular dystrophy: report of the guideline development,
dissemination, and implementation subcommittee of the American
Academy of Neurology and the Practice Issues Review Panel of the
American Association of Neuromuscular & Electrodiagnostic Medi-
cine. Neurology 2015;85:357–364.
45. Jansen M, van Alfen N, Nijhuis van der Sanden MW,
et al. Quantitative muscle ultrasound is a promising longitudinal
follow-up tool in Duchenne muscular dystrophy. Neuromusc Disord
2012;22:306–317.
46. Witting N, Andersen LK, Vissing J. Axial myopathy: an overlooked
feature of muscle diseases. Brain 2016;139:13–22.
47. Rijken NH, van der Kooi EL, Hendriks JC, et al. Skeletal muscle imag-
ing in facioscapulohumeral muscular dystrophy, pattern and asym-
metry of individual muscle involvement. Neuromusc Disord 2014;24:
1087–1096.
48. Wohlgemuth M, Horlings CGC, van der Kooi EL, et al. Respiratory
function in facioscapulohumeral muscular dystrophy 1. Neuromusc
Disord 2017;27:526–530.
49. Trevisan CP, Pastorello E, Ermani M, et al. Facioscapulohumeral mus-
cular dystrophy: a multicenter study on hearing function. Audiol
Neurootol 2008;13:1–6.
50. Fitzsimons RB. Retinal vascular disease and the pathogenesis of
facioscapulohumeral muscular dystrophy. A signalling message from
Wnt? Neuromusc Disord 2011;21:263–271.
51. Kalkman JS, Schillings ML, van der Werf SP, et al. Experienced
fatigue in facioscapulohumeral dystrophy, #myotonic |dystrophy, and
HMSN-I. J Neurol Neurosurg Psychiatry 2005;76:1406–1409.
52. Padua L, Aprile I, Frusciante R, et al. Quality of life and pain in
patients with facioscapulohumeral muscular dystrophy. Muscle Nerve
2009;40:200–205.
53. Houwen-van Opstal SL, Jansen M, van Alfen N, de Groot IJ.
Health-related quality of life and its relation to disease severity in
boys with Duchenne muscular dystrophy: satisfied boys, worrying
parents--a case-control study. J Child Neurol 2014;29:1486–1495.
54. Bergsma A, Janssen M, Geurts AC, Cup EH, de Groot IJM. Different
profiles of upper limb function in four types of neuromuscular disor-
ders. Neuromusc Disord 2017;27:1115–1122.
55. McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk
test and other clinical endpoints in duchenne muscular dystrophy:
reliability, #concurrent |validity, and minimal clinically important dif-
ferences from a multicenter study. Muscle Nerve 2013;48:357–368.
56. Bartels B, de Groot JF, Terwee CB. The six-minute walk test in
chronic pediatric conditions: a systematic review of measurement
properties. Phys Ther 2013;93:529–541.
57. Zaidman CM, Malkus EC, Connolly AM. Muscle ultrasound quantifies
disease progression over time in infants and young boys with duch-
enne muscular dystrophy. Muscle Nerve 2015;52:334–338.
58. Jansen M, van Alfen N, Geurts AC, de Groot IJ. Assisted bicycle
training delays functional deterioration in boys with Duchenne mus-
cular dystrophy: the randomized controlled trial “no use is disuse”.
Neurorehabil Neural Repair 2013;27:816–827.
59. Voet N, Bleijenberg G, De Groot I, et al. Both aerobic exercise train-
ing and cognitive behavior therapy reduce chronic fatigue in patients
with facioscapulohumeral muscular dystrophy: a randomized con-
trolled trial. Ann Phys Rehabil Med 2014;57:e96.
November 2018 637
Goselink et al: Facioscapulohumeral Dystrophy in Childhood
